Predicting response to opiate antagonists and placebo in the treatment of pathological gambling

[1]  B. K. Hartman,et al.  A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. , 2008, The Journal of clinical psychiatry.

[2]  John H. Krystal,et al.  Family History of Alcoholism Influences Naltrexone-Induced Reduction in Alcohol Drinking , 2007, Biological Psychiatry.

[3]  L. Ray,et al.  Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. , 2007, Archives of general psychiatry.

[4]  Robert A. Koeppe,et al.  Individual Differences in Reward Responding Explain Placebo-Induced Expectations and Effects , 2007, Neuron.

[5]  E. Hollander,et al.  Epidemiologic and clinical updates on impulse control disorders: a critical review , 2006, European Archives of Psychiatry and Clinical Neuroscience.

[6]  David Couper,et al.  Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. , 2006, JAMA.

[7]  E. Hollander,et al.  Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. , 2006, The American journal of psychiatry.

[8]  C. O'brien.  Anticraving medications for relapse prevention: a possible new class of psychoactive medications. , 2005, The American journal of psychiatry.

[9]  D. Oslin,et al.  A Functional Polymorphism of the μ-Opioid Receptor Gene is Associated with Naltrexone Response in Alcohol-Dependent Patients , 2003, Neuropsychopharmacology.

[10]  JaneR . Taylor,et al.  Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability. , 2003, The American journal of psychiatry.

[11]  R. Rosenheck,et al.  Naltrexone in the treatment of alcohol dependence. , 2001, The New England journal of medicine.

[12]  J. Monterosso,et al.  Predicting treatment response to naltrexone: the influence of craving and family history. , 2001, The American journal on addictions.

[13]  C. Blanco,et al.  Pathological gambling: addiction or compulsion? , 2001, Seminars in clinical neuropsychiatry.

[14]  Suck-Won Kim,et al.  Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling , 2001, Biological Psychiatry.

[15]  W R True,et al.  Common genetic vulnerability for pathological gambling and alcohol dependence in men. , 2000, Archives of general psychiatry.

[16]  E. Hollander,et al.  A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling , 2000, Biological Psychiatry.

[17]  R. Anton,et al.  Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. , 1999, The American journal of psychiatry.

[18]  B. Mason,et al.  A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. , 1999, Archives of general psychiatry.

[19]  E. Baráth,et al.  Fundamentals of Biostatistics. , 1992 .

[20]  H. Lesieur,et al.  The South Oaks Gambling Screen (SaGS): A New Instrument for the Identification of Pathological Gamblers , 2010 .

[21]  D. German,et al.  Electrophysiological evidence for excitation of rat ventral tegmental area dopamine neurons by morphine , 1984, Neuroscience.

[22]  D. Sheehan,et al.  The Anxiety Disease , 1984 .

[23]  A. Cools,et al.  Facilitation of self-stimulation behavior following intracerebral microinjections of opioids into the ventral tegmental area , 1979, Pharmacology Biochemistry and Behavior.

[24]  D. Jasinski,et al.  Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man. , 1973, Archives of general psychiatry.

[25]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[26]  M. Hamilton.  The assessment of anxiety states by rating. , 1959, The British journal of medical psychology.

[27]  J. Brewer,et al.  The neurobiology and genetics of impulse control disorders: relationships to drug addictions. , 2008, Biochemical pharmacology.

[28]  A. Stoessl,et al.  Placebo effect and dopamine release. , 2006, Journal of neural transmission. Supplementum.

[29]  E. Hollander,et al.  Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? , 2005, The American journal of psychiatry.

[30]  Eric Hollander,et al.  Reliability and Validity of the Pathological Gambling Adaptation of the Yale-Brown Obsessive-Compulsive Scale (PG-YBOCS) , 2005, Journal of Gambling Studies.

[31]  D. Oslin,et al.  A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. , 2003, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[32]  R. Lam,et al.  Bipolar spectrum disorders , 2002 .

[33]  S. Montgomery.  The failure of placebo-controlled studies. ECNP Consensus Meeting, September 13, 1997, Vienna. European College of Neuropsychopharmacology. , 1999, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology.

[34]  N. O'mara,et al.  Naltrexone in the treatment of alcohol dependence. , 1994, The Annals of pharmacotherapy.

[35]  T. Kosten,et al.  Role of opioid antagonists in treating intravenous cocaine abuse. , 1989, Life sciences.